Pfizer Share Price Today (PFIZER)
TODAY IN ONE LINE
PFIZER edged up 0.4% on above-average volume (5.0x avg), in line with Nifty's -0.0% move.
With a market cap of ₹21,490.46 Cr., it trades at a P/E of 29.89. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Pfizer flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 27.2% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 19.8%
- ●High Promoter HoldingPromoters hold 63.9% skin-in-the-game
- ●Steady Dividend YieldReliable 2.83% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 39.6% YoY
Latest Pfizer News
What changed recently?
Recent events, corporate actions, and announcements.
Pfizer Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Pfizer Limited, framed against the sector median so the premium or discount is obvious at a glance.
Pfizer Limited trades at a P/E of 29.89× and P/B of 5.14×, against the Healthcare sector median P/E of 45.48×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Pfizer Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Pfizer Limited — derived from the live tape, not yesterday's close.
Pfizer Limited last traded at ₹4,710.7 with an intraday range of ₹4,652.3–₹4,767.3 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹4710.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 4997.90 | +287.20 | +6.10% |
| R3 | 4882.90 | +172.20 | +3.66% |
| R2 | 4825.10 | +114.40 | +2.43% |
| R1 | 4767.90 | +57.20 | +1.21% |
| PIVOT | 4710.10 | -0.60 | -0.01% |
| CURRENT | 4710.70 | — | — |
| S1 | 4652.90 | -57.80 | -1.23% |
| S2 | 4595.10 | -115.60 | -2.45% |
| S3 | 4537.90 | -172.80 | -3.67% |
| S4 | 4422.90 | -287.80 | -6.11% |
PFIZER is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹4670.6–₹4702.2
Trading Inside opening range
Pfizer Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Pfizer Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Pfizer Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹21,490.46 Cr. and reported EPS of ₹157.72.
Pfizer segment analysis : revenue and profit mix.
Disclosed business segments at Pfizer with their share of revenue and profit, switchable between consolidated and standalone reporting.
Pfizer discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Pfizer Limited.
Our AI distills the core fundamental drivers supporting Pfizer Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Pfizer Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 33.59% and net margin 28.67% rank among sector's highest performers.
ROCE 27.20% and ROE 19.80% demonstrate efficient capital deployment and superior returns.
Debt-free balance sheet with zero total debt eliminates financial leverage risk entirely.
Promoter holding 63.92% signals strong long-term commitment and ownership alignment.
Cash per share ₹211.50 provides substantial liquidity and dividend sustainability.
Key Risks.
Latest quarterly EPS declined 39.6% YoY, signaling significant earnings contraction.
P/E 28.29x elevated relative to forward P/E 21.98x, suggesting valuation compression.
Price-to-book 5.15x indicates market values stock well above tangible net assets.
Payout ratio 82.42% limits reinvestment capacity for organic growth initiatives.
5-year revenue CAGR 0% reflects stagnant top-line expansion trajectory.
Flip Conditions.
Valuation risk. a P/E above 39 (~0.9× the sector multiple of 45.5) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 15% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 1.42%.
Pfizer Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Pfizer Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Pfizer Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Pfizer Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Pfizer Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Pfizer Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Pfizer Limited stood at 23.7% of traded volume, against a 20-day average of 52.3%.
Pfizer announcements: results, concalls, ratings, M&A.
Filings Pfizer sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Pfizer files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 58 documents below.
News Verification
The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India,…
News Verification
The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India,…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.
Updates
Pfizer Limited has informed the Exchange regarding 'Letter to shareholders providing the weblink to access the Annual Report for Financial Year 2025…
Copy of Newspaper Publication
Pfizer Limited has informed the Exchange about Copy of Newspaper Publication
Pfizer dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Pfizer has declared, sequenced by announce and record date.
Pfizer corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Pfizer Limited: business, sector, key facts.
What Pfizer Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Pfizer Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: PFIZER, BSE: 500680.
Pfizer Limited is a multinational pharmaceutical company with a significant presence in India and international markets. Its core business revolves around the manufacturing, marketing, trading, and export of a wide range of pharmaceutical products. This encompasses a diverse portfolio catering to numerous therapeutic areas, reflecting a broad reach across various health conditions and patient needs.
The company's product portfolio spans a considerable number of therapeutic categories. These include treatments for neurological and central nervous system disorders (neuro/CNS), hormonal imbalances, cardiovascular diseases, haemophilia, infectious diseases (anti-infectives), gynecological conditions, pain management (analgesics), orthopedic issues, cancer (oncology), urological problems, parasitic infections, gastrointestinal disorders, respiratory illnesses, and vaccinations. Furthermore, Pfizer also offers vitamins, minerals, and nutritional supplements.
Pfizer's customer base is extensive and multifaceted. It directly serves healthcare providers, both government and private hospitals, and retail pharmacies. The company's distribution network relies on a system of independent distributors to ensure wide market reach and accessibility of its products. This distribution model allows Pfizer to effectively serve its diverse customer base across various geographical locations and healthcare settings.
In addition to its extensive product offerings, Pfizer Limited also provides internal medicine and anti-infective services directly to hospitals and nursing homes. This reflects a commitment to providing comprehensive healthcare solutions beyond just the supply of pharmaceutical products. This integrated approach strengthens its relationships with healthcare institutions and allows for more holistic patient care.
Established in 1950 and headquartered in Mumbai, India, Pfizer Limited has a long history of operation in the pharmaceutical industry. Its continued success is rooted in its diverse product portfolio, wide-ranging customer base, and established distribution network. The company's commitment to various therapeutic areas underscores its dedication to addressing a broad spectrum of healthcare needs globally.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Pfizer Limited (PFIZER).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Pfizer Limited (PFIZER)?
The current share price of Pfizer Limited (PFIZER) is ₹4,710.7. Today, the stock has gained by ₹18.10 (0.39%), trading in a range of ₹4,652.3 to ₹4,767.3. The stock opened at ₹4,700 with a trading volume of 1,19,614 shares.
02Is Pfizer Limited stock a good investment for long-term?
Pfizer Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹21,490.46 crores, P/E ratio of 29.89, ROE of 19.80%, and ROCE of 27.20%. The dividend yield stands at 2.83%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Pfizer Limited stock?
The 52-week high price of Pfizer Limited (PFIZER) is ₹5,873.5, while the 52-week low is ₹4,360.1. Currently trading at ₹4,710.7, the stock is 23.2% away from its 52-week low and 19.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Pfizer Limited stock at the current price?
Whether to buy Pfizer Limited stock at ₹4,710.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 29.89 and P/B ratio of 5.14. Today's performance shows a gain of 0.39%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Pfizer Limited and when is the next dividend?
Pfizer Limited offers a dividend yield of 2.83%, which means for every ₹100 invested at the current price of ₹4,710.7, you can expect to receive approximately ₹2.83 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Pfizer Limited?
Pfizer Limited's key financial metrics include: P/E Ratio: 29.89, P/B Ratio: 5.14, ROE: 19.80%, ROCE: 27.20%, Dividend Yield: 2.83%, EPS: ₹157.72, Book Value: ₹918.74, and Debt-to-Equity: 0.00. The company's market cap stands at ₹21,490.46 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Pfizer Limited stock performing today in the market?
Pfizer Limited stock opened at ₹4,700 and is currently trading at ₹4,710.7, showing a gain of ₹18.10 (0.39%). The intraday high is ₹4,767.3 and low is ₹4,652.3. The trading volume stands at 1,19,614 shares, indicating moderate market participation today.
08What is the P/E ratio of Pfizer Limited and what does it indicate?
Pfizer Limited has a Price-to-Earnings (P/E) ratio of 29.89, which means investors are willing to pay ₹29.89 for every ₹1 of earnings. With an EPS of ₹157.72, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Pfizer Limited (PFIZER) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.